Compare · INGN vs ZBH
INGN vs ZBH
Side-by-side comparison of Inogen Inc (INGN) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INGN and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $16.05B, about 84.1x INGN ($190.7M).
- Both names hit the wire about 7 times in the past 4 weeks.
- ZBH has more recent analyst coverage (25 ratings vs 11 for INGN).
- Company
- Inogen Inc
- Zimmer Biomet Holdings Inc.
- Price
- $6.97-1.97%
- $82.91+0.62%
- Market cap
- $190.7M
- $16.05B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 7
- 7
- Recent ratings
- 11
- 25
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest INGN
- SEC Form DEF 14A filed by Inogen Inc
- Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form PRE 14A filed by Inogen Inc
- SEC Form 4 filed by Richardson Jason Andrew
- SEC Form 3 filed by new insider Richardson Jason Andrew
- Inogen Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Inogen Announces the Appointment of Vafa Jamali to Board of Directors
- Inogen Announces Participation in the 25th Annual Needham Virtual Healthcare Conference
- Inogen Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest ZBH
- SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zimmer Biomet Announces First Quarter 2026 Financial Results
- Zimmer Biomet Announces Chief Financial Officer Transition
- Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
- Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
- SEC Form 4 filed by Noor Jehanzeb
- SEC Form 4 filed by Jafry Syed A.
- SEC Form 4 filed by Kolli Sreelakshmi